We are live on ! Find out more
DCMIC

Decheng Capital Management III (Cayman) Portfolio holdings

AUM $300M
1-Year Est. Return 15.74%
This Fund
S&P 500
This Quarter Est. Return
-10.5%
1 Year Est. Return
+15.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$300M
AUM Growth
-$19.2M
Cap. Flow
+$40.1M
Cap. Flow %
13.37%
Top 10 Hldgs %
79.17%
Holding
32
New
7
Increased
1
Reduced
2
Closed
6

Top Buys

1
ALPN
Alpine Immune Sciences Inc
ALPN
+$82.6M
2
ROIV icon
Roivant Sciences
ROIV
+$16.5M
3
LNTH icon
Lantheus
LNTH
+$10.4M
4
AURA icon
Aura Biosciences
AURA
+$9.36M
5
IMGN
Immunogen Inc
IMGN
+$6.92M

Top Sells

1
ALP.PRN
Alabama Power Co 5.20% CL-A PRF
ALP.PRN
+$69M
2
APGN
Apexigen, Inc. Common Stock
APGN
+$814K
3
ACET icon
Adicet Bio
ACET
+$674K
4
SLRN
ACELYRIN
SLRN
+$130K
5
NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
+$92.5K

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACET icon
26
Adicet Bio
ACET
$76.8M
$274K 0.09%
12,513
-19,091
-60% -$674K
NBSE
27
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-50,000
Closed -$92.5K
APGN
28
DELISTED
Apexigen, Inc. Common Stock
APGN
– –
-1,894,551
Closed -$814K
ALP.PRN
29
DELISTED
Alabama Power Co 5.20% CL-A PRF
ALP.PRN
– –
-6,708,288
Closed -$69M
1
2

Similar funds

IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
KBC
Key Bridge Compliance $319M AUM

Decheng Capital Management III (Cayman)'s Q3 2023 Portfolio in Review

As of Q3 2023, Decheng Capital Management III (Cayman) held 32 positions worth $300M, down 6% from $319M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Decheng Capital Management III (Cayman) deployed $40.1M of net new capital in Q3 2023, opening 7 new positions and adding to 1 existing holding. Its largest new stake was Alpine Immune Sciences Inc: 6,708,288 shares worth $76.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 71% a quarter earlier.

On the sell side, the largest reduction was Adicet Bio, an estimated $674K trimmed.

  • Decheng Capital Management III (Cayman)'s largest Q3 2023 buy was Alpine Immune Sciences Inc: 6,708,288 shares worth $76.8M.
  • Decheng Capital Management III (Cayman) added most to Aura Biosciences in Q3 2023, an estimated $9.36M increase.
  • Decheng Capital Management III (Cayman)'s biggest Q3 2023 reduction was Adicet Bio, cutting an estimated $674K.
  • Decheng Capital Management III (Cayman) fully exited Alabama Power Co 5.20% CL-A PRF in Q3 2023, selling an estimated $69M.
  • Decheng Capital Management III (Cayman)'s ten largest holdings make up 79% of its $300M portfolio in Q3 2023.
  • Decheng Capital Management III (Cayman) opened 7 new positions and closed 6 in Q3 2023.
  • Decheng Capital Management III (Cayman)'s portfolio value fell 6% quarter-over-quarter to $300M.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q3 2023, filed 13 Nov 2023.